AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Effects: Isoxicam, like other NSAIDs, can cause gastrointestinal adverse effects such as stomach ulcers, bleeding, and perforation. These complications may lead to symptoms like abdominal pain, black or tarry stools, vomiting blood, and indigestion.
Cardiovascular Risks: NSAIDs, including isoxicam, have been associated with an increased risk of cardiovascular events such as heart attack and stroke, especially when used at high doses or for long durations. This risk may be higher in individuals with pre-existing cardiovascular conditions or those who have risk factors such as hypertension, diabetes, or smoking.
Renal Toxicity: Isoxicam can impair kidney function and may lead to kidney damage, particularly in individuals with underlying kidney disease, dehydration, or those taking other nephrotoxic medications. Symptoms of renal toxicity include decreased urine output, fluid retention, swelling, and electrolyte imbalances.
Hepatotoxicity: Rarely, isoxicam use has been associated with liver damage or hepatotoxicity, characterized by symptoms such as jaundice, abdominal pain, nausea, vomiting, and elevated liver enzymes.
Hematological Effects: Isoxicam may affect blood clotting and increase the risk of bleeding disorders, such as thrombocytopenia (low platelet count) or coagulopathy (impaired blood clotting). Patients should be monitored for signs of bleeding, such as easy bruising, prolonged bleeding from cuts, or unusual bleeding.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 2.1 | 0.3 | 6 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.4 | 1 | 0.4 |
| Allergies | 1.4 | 1.9 | -0.36 |
| Allergy to milk products | 1 | 0.6 | 0.67 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 3.4 | 2.5 | 0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.7 | 2.29 |
| Ankylosing spondylitis | 2.4 | 0.9 | 1.67 |
| Anorexia Nervosa | 0.6 | 1.7 | -1.83 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 3.4 | 2.7 | 0.26 |
| Atherosclerosis | 0.9 | 1.1 | -0.22 |
| Atrial fibrillation | 2 | 0.6 | 2.33 |
| Autism | 3.9 | 4.3 | -0.1 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 0.3 | 0.8 | -1.67 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.9 | 0.5 | 0.8 |
| Carcinoma | 2.6 | 1.4 | 0.86 |
| Celiac Disease | 1.3 | 2.4 | -0.85 |
| Cerebral Palsy | 1.5 | 0.8 | 0.88 |
| Chronic Fatigue Syndrome | 1.4 | 1.9 | -0.36 |
| Chronic Kidney Disease | 1.3 | 1.2 | 0.08 |
| Chronic Lyme | 0 | 0.8 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 0.6 | 0.7 | -0.17 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.8 | -1.67 |
| Cognitive Function | 2 | 1.4 | 0.43 |
| Colorectal Cancer | 4.7 | 1.1 | 3.27 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.3 | 1.4 | -3.67 |
| COVID-19 | 2.6 | 3.7 | -0.42 |
| Crohn's Disease | 3.8 | 3.7 | 0.03 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.1 | -1.1 | |
| deep vein thrombosis | 1.5 | 1.1 | 0.36 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 3.9 | 4.4 | -0.13 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.9 | 0.7 | 0.29 |
| Endometriosis | 1.4 | 1.4 | 0 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 1.5 | 1.6 | -0.07 |
| erectile dysfunction | 0.6 | 0.3 | 1 |
| Fibromyalgia | 1.4 | 0.6 | 1.33 |
| Functional constipation / chronic idiopathic constipation | 1.6 | 1.2 | 0.33 |
| gallstone disease (gsd) | 0.9 | 1.5 | -0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.6 | 1 |
| Generalized anxiety disorder | 1.2 | 1.8 | -0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.3 | 2.33 |
| Graves' disease | 0.9 | 2.3 | -1.56 |
| Gulf War Syndrome | 0.3 | 1.3 | -3.33 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 2.6 | 1.2 | 1.17 |
| Heart Failure | 1.3 | 1.2 | 0.08 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.7 | -1.33 |
| hyperglycemia | 1.1 | 1.6 | -0.45 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypertension (High Blood Pressure | 2.8 | 2.2 | 0.27 |
| Hypothyroidism | 0.3 | 0.3 | 0 |
| Hypoxia | 1.5 | 0.3 | 4 |
| IgA nephropathy (IgAN) | 0.9 | 1.6 | -0.78 |
| Inflammatory Bowel Disease | 2.6 | 3.8 | -0.46 |
| Insomnia | 1.6 | 2.7 | -0.69 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 4.4 | 3 | 0.47 |
| ischemic stroke | 1.6 | 0.8 | 1 |
| Liver Cirrhosis | 3.7 | 4.2 | -0.14 |
| Long COVID | 2.4 | 3.1 | -0.29 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.1 | 1.3 | -12 |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 0.6 | -1 |
| ME/CFS without IBS | 0.3 | 1.2 | -3 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.9 | -1.25 |
| Metabolic Syndrome | 3 | 4.3 | -0.43 |
| Mood Disorders | 4.4 | 3.1 | 0.42 |
| multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
| Multiple Sclerosis | 2.7 | 1.6 | 0.69 |
| Multiple system atrophy (MSA) | 1.1 | 0.3 | 2.67 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 2 | -2 | |
| Neuropathy (all types) | 0.6 | 0.7 | -0.17 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2.8 | -0.08 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 5.1 | 5.8 | -0.14 |
| obsessive-compulsive disorder | 1.2 | 2.4 | -1 |
| Osteoarthritis | 0.6 | 1.2 | -1 |
| Osteoporosis | 1.1 | 1.8 | -0.64 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 3.6 | 3 | 0.2 |
| Polycystic ovary syndrome | 1.7 | 2 | -0.18 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 1.2 | 0.6 | 1 |
| Primary sclerosing cholangitis | 1.5 | 1.5 | |
| Psoriasis | 1.3 | 1.5 | -0.15 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.4 | 2.6 | 0.31 |
| Rosacea | 0.3 | 0.8 | -1.67 |
| Schizophrenia | 3.1 | 2 | 0.55 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 1.2 | 1.2 | 0 |
| Sleep Apnea | 1.4 | 0.8 | 0.75 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.1 | 11 |
| Stress / posttraumatic stress disorder | 2.3 | 1.8 | 0.28 |
| Systemic Lupus Erythematosus | 1.4 | 1.4 | 0 |
| Tic Disorder | 0.6 | 0.9 | -0.5 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 1.6 | 2.1 | -0.31 |
| Type 2 Diabetes | 3 | 4 | -0.33 |
| Ulcerative colitis | 3 | 2.5 | 0.2 |
| Unhealthy Ageing | 2.4 | 1.5 | 0.6 |
| Vitiligo | 1.2 | 0.6 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
